000151628 001__ 151628
000151628 005__ 20250319155217.0
000151628 0247_ $$2doi$$a10.3390/pharmaceutics13081176
000151628 0248_ $$2sideral$$a126194
000151628 037__ $$aART-2021-126194
000151628 041__ $$aeng
000151628 100__ $$aPérez-Laguna V.
000151628 245__ $$aIn vitro effect of photodynamic therapy with different lights and combined or uncombined with chlorhexidine on candida spp.
000151628 260__ $$c2021
000151628 5060_ $$aAccess copy available to the general public$$fUnrestricted
000151628 5203_ $$aCandidiasis is very common and complicated to treat in some cases due to increased resistance to antifungals. Antimicrobial photodynamic therapy (aPDT) is a promising alternative treatment. It is based on the principle that light of a specific wavelength activates a photosensitizer molecule resulting in the generation of reactive oxygen species that are able to kill pathogens. The aim here is the in vitro photoinactivation of three strains of Candida spp., Candida albicans ATCC 10231, Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258, using aPDT with different sources of irradiation and the photosensitizer methylene blue (MB), alone or in combination with chlorhexidine (CHX). Irradiation was carried out at a fluence of 18 J/cm2 with a light-emitting diode (LED) lamp emitting in red (625 nm) or a white metal halide lamp (WMH) that emits at broad-spectrum white light (420–700 nm). After the photodynamic treatment, the antimicrobial effect is evaluated by counting colony forming units (CFU). MB-aPDT produces a 6 log10 reduction in the number of CFU/100 µL of Candida spp., and the combination with CHX enhances the effect of photoinactivation (effect achieved with lower concentration of MB). Both lamps have similar efficiencies, but the WMH lamp is slightly more efficient. This work opens the doors to a possible clinical application of the combination for resistant or persistent forms of Candida infections.
000151628 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B10_17R$$9info:eu-repo/grantAgreement/ES/DGA/B18_17R$$9info:eu-repo/grantAgreement/ES/MINECO/CTQ2013-48767-C3-2-R
000151628 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000151628 590__ $$a6.525$$b2021
000151628 591__ $$aPHARMACOLOGY & PHARMACY$$b39 / 279 = 0.14$$c2021$$dQ1$$eT1
000151628 592__ $$a0.922$$b2021
000151628 593__ $$aPharmaceutical Science$$c2021$$dQ1
000151628 594__ $$a6.0$$b2021
000151628 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000151628 700__ $$aBarrena-López Y.
000151628 700__ $$0(orcid)0000-0001-8034-3617$$aGilaberte Y.$$uUniversidad de Zaragoza
000151628 700__ $$0(orcid)0000-0001-7294-245X$$aRezusta A.$$uUniversidad de Zaragoza
000151628 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología
000151628 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología
000151628 773__ $$g13, 8 (2021), 1176 [13 pp.]$$pPharmaceutics$$tPharmaceutics$$x1999-4923
000151628 8564_ $$s528323$$uhttps://zaguan.unizar.es/record/151628/files/texto_completo.pdf$$yVersión publicada
000151628 8564_ $$s2740299$$uhttps://zaguan.unizar.es/record/151628/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000151628 909CO $$ooai:zaguan.unizar.es:151628$$particulos$$pdriver
000151628 951__ $$a2025-03-19-14:19:35
000151628 980__ $$aARTICLE